Meeting
2022 ASCO Genitourinary Cancers Symposium
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.
Authors
Shilpa Gupta
Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
Shilpa Gupta , Cathy Su , Abhijeet Bhanegaonkar , Shaloo Gupta , Sheena Thakkar , deMauri S Mackie , Geeta Devgan , Howard Katzenstein , Frank Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 456)
DOI
10.1200/JCO.2022.40.6_suppl.456
Abstract #
456
Poster Bd #
C10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
First Author: Melissa Kirker
Poster
2018 Genitourinary Cancers Symposium
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
First Author: Michaela Ann Dinan
Poster
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.
First Author: Akshat Saxena
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.
First Author: Petros Grivas